Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response matches the FDA label: DUPIXENT is explicitly not indicated for the relief of acute bronchospasm or status asthmaticus, and the warnings state it should not be used for acute symptoms/exacerbations including acute bronchospasm/status asthmaticus.
Category Scores
Accurate Statements
DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.
Section 1.2 Asthma: "DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus."
DUPIXENT should not be used to treat acute bronchospasm or status asthmaticus.
Section 5.4: "Do not use DUPIXENT to treat acute bronchospasm or status asthmaticus."
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The response correctly emphasizes the label’s limitation against using DUPIXENT for acute bronchospasm/status asthmaticus, which is safety-relevant.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement